期刊
CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 58, 期 12, 页码 1935-1939出版社
SPRINGER
DOI: 10.1007/s00262-008-0636-9
关键词
Aging; Dendritic cells; Immunotherapy
资金
- NIA NIH HHS [R01 AG020628, R56 AG020628, R01 AG020628-04, R01 AG028268, R01 AG028268-04] Funding Source: Medline
Effective cancer immunotherapy depends on the body's ability to generate tumor antigen-presenting cells and tumor-reactive effector lymphocytes. As the most potent antigen presenting cells (APCs), dendritic cells (DCs) are capable of sensitizing T cells to new and recall antigens. Clinical trials of antigen-pulsed autologous DCs have been conducted in patients with a number of hematological and solid cancers, including malignant melanoma, lymphoma, myeloma, and non-small cell lung cancer. These studies suggest that antigen-loaded DC vaccination is a potentially safe and effective cancer therapy. However, the clinical results have been variable. Since the elderly are preferentially affected by diseases targeted by DC-directed immunotherapy, it is quite striking that few studies to date have focused on the effect of aging on DC function, a key aspect of optimal immunotherapy design in an aging population. In the present paper, we will discuss the consequences of aging on murine bone marrow-derived DC function and their use in cancer immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据